Correction of anemia with continuous erythropoietin receptor activator in korean patients on long-term hemodialysis

Journal of Korean Medical Science

Volumn 29, Issue 1, 2014, Pages 76-83

  Oh, Jieun ^a   Joo, Kwon Wook ^b   Chin, Ho Jun ^c   Chae, Dong Wan ^c   Kim, Sung Gyun ^a   Kim, Soo Jin ^a   Chung, Wookyung ^d   Kim, Sejoong ^c   Huh, Wooseong ^e   Oh, Ha Young ^e   Choi, Bum Soon ^f   Yang, Chul Woo ^f   Kim, Suhnggwon ^b  

^a Hallym University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Gachon University   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Anemia correction; Chronic; Continuous erythropoietin receptor activator; Kidney failure; Renal dialysis

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; HEMOGLOBIN; MACROGOL DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ANEMIA; ANEMIA CORRECTION; ARTICLE; CHRONIC KIDNEY FAILURE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; SOUTH KOREA;

ANEMIA CORRECTION; CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

ANEMIA; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RECOMBINANT PROTEINS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; REPUBLIC OF KOREA;

EID: 84907424093     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.1.76     Document Type: Article

References (17)

1. Henry DH, Bowers P, Romano MT, Provenzano R. Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004; 164: 262-76.
2. Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chron-ic kidney disease. Drugs 2008; 68: 1139-56.
3. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 1211-5.
4. Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U. Efficacy of intravenous me-thoxy polyethylene glycol-epoetin beta administered every 2 weeks com-pared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007; 50: 989-1000.
5. Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, Locatelli F, Dougherty FC, Beyer U; ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008; 3: 337-47.
6. Levin NW, Fishbane S, Cañedo FV, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D; MAXIMA Study Investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiori-ty trial (MAXIMA). Lancet 2007; 370: 1415-21.
7. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2: 637-46.
8. Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008; 23: 3654-61.
9. Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U. C.E.R.A. maintains stable control of he-moglobin in patients with chronic kidney disease on dialysis when ad-ministered once every two weeks. Am J Nephrol 2008; 28: 280-9.
10. Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K. Resid-ual renal function improves outcome in incremental haemodialysis de-spite reduced dialysis dose. Nephrol Dial Transplant 2009; 24: 2502-10.
11. Penne EL, van der Weerd NC, Grooteman MP, Mazairac AH, van den Dorpel MA, Nubé MJ, Bots ML, Lévesque R, ter Wee PM, Blankestijn PJ. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 281-9.
12. Locatelli F, Reigner B. C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opin Inves-tig Drugs 2007; 16: 1649-61.
13. Fishbane S, Pannier A, Liogier X, Jordan P, Dougherty FC, Reigner B. Pharmacokinetic and pharmacodynamic properties of methoxy poly-ethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol 2007; 47: 1390-7.
14. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19: ii1-47.
15. KDOQI; National Kidney Foundation. KDOQI clinical practice guide-lines and clinical practice recommendations for anemia in chronic kid-ney disease. Am J Kidney Dis 2006; 47: S11-145.
16. Fliser D, Kleophas W, Dellanna F, Winkler RE, Backs W, Kraatz U, Fass-binder W, Wizemann V, Strack G. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin 2010; 26: 1083-9.
17. Weinreich T, Leistikow F, Hartmann HG, Vollgraf G, Dellanna F; SESAM Study Group. Monthly continuous erythropoietin receptor activator treat-ment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients. Hemodial Int 2012; 16: 11-9.